Eosinophil chemotactic factor-L (ECF-L) enhances osteoclast formation by increasing in osteoclast precursors expression of LFA-1 and ICAM-1

Veronica Garcia-Palacios, Ho Yeon Chung, Sun Jin Choi, Aliye Sarmasik, Noriyoshi Kurihara, Jun Won Lee, Deborah L. Galson, Robert Collins, G. David Roodman

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

ECF-L is a novel autocrine stimulator of osteoclast (OCL) formation that enhances the effects of 1,25-(OH)2D3 and RANK ligand (RANKL) and is increased in inflammatory conditions such as rheumatoid arthritis. ECF-L acts at the later stages of OCL formation and does not increase RANKL expression. Thus, its mechanism of action is unclear. Therefore, RAW 264.7 cells and M-CSF-dependent murine bone marrow macrophage (MDBM) cells were treated with RANKL and/or with recombinant ECF-L expressed as a Fc fusion protein (ECF-L-Fc) to determine their effects on NF-κB, AP-1 and JNK activity, and on the expression of the adhesion molecules that have been implicated in OCL formation. These parameters were measured by semiquantitative and PCR and Western blot analysis. In addition, the role of ICAM-1 was further assessed by treating normal mouse marrow cultures with ECF-L-Fc and 10- 10 M 1,25-(OH)2D3 in the presence or absence of a blocking ICAM-1 antibody or treating marrow cultures from ICAM-1 knockout mice with ECF-L and 1,25-(OH)2D3. ECF-L-Fc by itself only modestly increased NF-κB binding and JNK activity in RAW 264.7 cells, which was further enhanced by RANKL. In contrast, ECF-L-Fc increased LFA-1α and ICAM-1 mRNA levels 1.8-fold in mouse marrow cultures, and anti-ICAM-1 almost completely inhibited OCL formation induced by 10- 10 M 1,25-(OH)2D3 and ECF-L. Furthermore, ECF-L did not increase OCL formation in marrow cultures from ICAM-1 knockout mice. Taken together, these results demonstrate that ECF-L enhances RANKL and 1,25-(OH)2D3-induced OCL formation by increasing adhesive interactions between OCL precursors through increased expression of ICAM-1 and LFA-1.

Original languageEnglish (US)
Pages (from-to)316-322
Number of pages7
JournalBone
Volume40
Issue number2
DOIs
StatePublished - Feb 2007
Externally publishedYes

Fingerprint

Eosinophil Chemotactic Factors
Lymphocyte Function-Associated Antigen-1
Osteoclasts
Intercellular Adhesion Molecule-1
RANK Ligand
Bone Marrow
Knockout Mice
Macrophage Colony-Stimulating Factor
Transcription Factor AP-1
Bone Marrow Cells
Adhesives
Rheumatoid Arthritis
Western Blotting
Macrophages

Keywords

  • ECF-L
  • ICAM-1
  • LFA-1
  • Osteoclast
  • RANKL

ASJC Scopus subject areas

  • Physiology
  • Hematology

Cite this

Eosinophil chemotactic factor-L (ECF-L) enhances osteoclast formation by increasing in osteoclast precursors expression of LFA-1 and ICAM-1. / Garcia-Palacios, Veronica; Yeon Chung, Ho; Jin Choi, Sun; Sarmasik, Aliye; Kurihara, Noriyoshi; Won Lee, Jun; Galson, Deborah L.; Collins, Robert; Roodman, G. David.

In: Bone, Vol. 40, No. 2, 02.2007, p. 316-322.

Research output: Contribution to journalArticle

Garcia-Palacios, Veronica ; Yeon Chung, Ho ; Jin Choi, Sun ; Sarmasik, Aliye ; Kurihara, Noriyoshi ; Won Lee, Jun ; Galson, Deborah L. ; Collins, Robert ; Roodman, G. David. / Eosinophil chemotactic factor-L (ECF-L) enhances osteoclast formation by increasing in osteoclast precursors expression of LFA-1 and ICAM-1. In: Bone. 2007 ; Vol. 40, No. 2. pp. 316-322.
@article{adc39a6bc43e4523aaa5666ab672c411,
title = "Eosinophil chemotactic factor-L (ECF-L) enhances osteoclast formation by increasing in osteoclast precursors expression of LFA-1 and ICAM-1",
abstract = "ECF-L is a novel autocrine stimulator of osteoclast (OCL) formation that enhances the effects of 1,25-(OH)2D3 and RANK ligand (RANKL) and is increased in inflammatory conditions such as rheumatoid arthritis. ECF-L acts at the later stages of OCL formation and does not increase RANKL expression. Thus, its mechanism of action is unclear. Therefore, RAW 264.7 cells and M-CSF-dependent murine bone marrow macrophage (MDBM) cells were treated with RANKL and/or with recombinant ECF-L expressed as a Fc fusion protein (ECF-L-Fc) to determine their effects on NF-κB, AP-1 and JNK activity, and on the expression of the adhesion molecules that have been implicated in OCL formation. These parameters were measured by semiquantitative and PCR and Western blot analysis. In addition, the role of ICAM-1 was further assessed by treating normal mouse marrow cultures with ECF-L-Fc and 10- 10 M 1,25-(OH)2D3 in the presence or absence of a blocking ICAM-1 antibody or treating marrow cultures from ICAM-1 knockout mice with ECF-L and 1,25-(OH)2D3. ECF-L-Fc by itself only modestly increased NF-κB binding and JNK activity in RAW 264.7 cells, which was further enhanced by RANKL. In contrast, ECF-L-Fc increased LFA-1α and ICAM-1 mRNA levels 1.8-fold in mouse marrow cultures, and anti-ICAM-1 almost completely inhibited OCL formation induced by 10- 10 M 1,25-(OH)2D3 and ECF-L. Furthermore, ECF-L did not increase OCL formation in marrow cultures from ICAM-1 knockout mice. Taken together, these results demonstrate that ECF-L enhances RANKL and 1,25-(OH)2D3-induced OCL formation by increasing adhesive interactions between OCL precursors through increased expression of ICAM-1 and LFA-1.",
keywords = "ECF-L, ICAM-1, LFA-1, Osteoclast, RANKL",
author = "Veronica Garcia-Palacios and {Yeon Chung}, Ho and {Jin Choi}, Sun and Aliye Sarmasik and Noriyoshi Kurihara and {Won Lee}, Jun and Galson, {Deborah L.} and Robert Collins and Roodman, {G. David}",
year = "2007",
month = "2",
doi = "10.1016/j.bone.2006.08.004",
language = "English (US)",
volume = "40",
pages = "316--322",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Eosinophil chemotactic factor-L (ECF-L) enhances osteoclast formation by increasing in osteoclast precursors expression of LFA-1 and ICAM-1

AU - Garcia-Palacios, Veronica

AU - Yeon Chung, Ho

AU - Jin Choi, Sun

AU - Sarmasik, Aliye

AU - Kurihara, Noriyoshi

AU - Won Lee, Jun

AU - Galson, Deborah L.

AU - Collins, Robert

AU - Roodman, G. David

PY - 2007/2

Y1 - 2007/2

N2 - ECF-L is a novel autocrine stimulator of osteoclast (OCL) formation that enhances the effects of 1,25-(OH)2D3 and RANK ligand (RANKL) and is increased in inflammatory conditions such as rheumatoid arthritis. ECF-L acts at the later stages of OCL formation and does not increase RANKL expression. Thus, its mechanism of action is unclear. Therefore, RAW 264.7 cells and M-CSF-dependent murine bone marrow macrophage (MDBM) cells were treated with RANKL and/or with recombinant ECF-L expressed as a Fc fusion protein (ECF-L-Fc) to determine their effects on NF-κB, AP-1 and JNK activity, and on the expression of the adhesion molecules that have been implicated in OCL formation. These parameters were measured by semiquantitative and PCR and Western blot analysis. In addition, the role of ICAM-1 was further assessed by treating normal mouse marrow cultures with ECF-L-Fc and 10- 10 M 1,25-(OH)2D3 in the presence or absence of a blocking ICAM-1 antibody or treating marrow cultures from ICAM-1 knockout mice with ECF-L and 1,25-(OH)2D3. ECF-L-Fc by itself only modestly increased NF-κB binding and JNK activity in RAW 264.7 cells, which was further enhanced by RANKL. In contrast, ECF-L-Fc increased LFA-1α and ICAM-1 mRNA levels 1.8-fold in mouse marrow cultures, and anti-ICAM-1 almost completely inhibited OCL formation induced by 10- 10 M 1,25-(OH)2D3 and ECF-L. Furthermore, ECF-L did not increase OCL formation in marrow cultures from ICAM-1 knockout mice. Taken together, these results demonstrate that ECF-L enhances RANKL and 1,25-(OH)2D3-induced OCL formation by increasing adhesive interactions between OCL precursors through increased expression of ICAM-1 and LFA-1.

AB - ECF-L is a novel autocrine stimulator of osteoclast (OCL) formation that enhances the effects of 1,25-(OH)2D3 and RANK ligand (RANKL) and is increased in inflammatory conditions such as rheumatoid arthritis. ECF-L acts at the later stages of OCL formation and does not increase RANKL expression. Thus, its mechanism of action is unclear. Therefore, RAW 264.7 cells and M-CSF-dependent murine bone marrow macrophage (MDBM) cells were treated with RANKL and/or with recombinant ECF-L expressed as a Fc fusion protein (ECF-L-Fc) to determine their effects on NF-κB, AP-1 and JNK activity, and on the expression of the adhesion molecules that have been implicated in OCL formation. These parameters were measured by semiquantitative and PCR and Western blot analysis. In addition, the role of ICAM-1 was further assessed by treating normal mouse marrow cultures with ECF-L-Fc and 10- 10 M 1,25-(OH)2D3 in the presence or absence of a blocking ICAM-1 antibody or treating marrow cultures from ICAM-1 knockout mice with ECF-L and 1,25-(OH)2D3. ECF-L-Fc by itself only modestly increased NF-κB binding and JNK activity in RAW 264.7 cells, which was further enhanced by RANKL. In contrast, ECF-L-Fc increased LFA-1α and ICAM-1 mRNA levels 1.8-fold in mouse marrow cultures, and anti-ICAM-1 almost completely inhibited OCL formation induced by 10- 10 M 1,25-(OH)2D3 and ECF-L. Furthermore, ECF-L did not increase OCL formation in marrow cultures from ICAM-1 knockout mice. Taken together, these results demonstrate that ECF-L enhances RANKL and 1,25-(OH)2D3-induced OCL formation by increasing adhesive interactions between OCL precursors through increased expression of ICAM-1 and LFA-1.

KW - ECF-L

KW - ICAM-1

KW - LFA-1

KW - Osteoclast

KW - RANKL

UR - http://www.scopus.com/inward/record.url?scp=33845999571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845999571&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2006.08.004

DO - 10.1016/j.bone.2006.08.004

M3 - Article

C2 - 16996813

AN - SCOPUS:33845999571

VL - 40

SP - 316

EP - 322

JO - Bone

JF - Bone

SN - 8756-3282

IS - 2

ER -